Clinical Trials Logo

Bipolar 1 Disorder clinical trials

View clinical trials related to Bipolar 1 Disorder.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03386851 Completed - Schizophrenia Clinical Trials

Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder

Start date: December 13, 2016
Phase:
Study type: Observational

This is a Post-Marketing Surveillance (PMS) of Abilify Maintena® Injections in accordance with Korean regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: Ministry of Food and Drug Safety(MFDS) Notification).

NCT ID: NCT02050854 Completed - Schizophrenia Clinical Trials

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

Start date: December 2013
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are currently on treatment with oral aripiprazole.

NCT ID: NCT01396291 Completed - Bipolar 1 Disorder Clinical Trials

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

Start date: December 2011
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the efficacy and safety of asenapine as compared to placebo in preventing the recurrence of mood episodes after stabilization of an acute/manic mixed episode in participants with Bipolar 1 Disorder. After a Screening Period, each participant will receive open-label asenapine and matching placebo for 12 to 16 weeks. Participants who meet stabilization criteria may then be randomized into one of the two study arms (asenapine or matching placebo) to receive double-blind treatment for up to an additional 26-weeks.

NCT ID: NCT00764478 Completed - Bipolar 1 Disorder Clinical Trials

Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)

Start date: April 6, 2012
Phase: Phase 3
Study type: Interventional

This trial will study the efficacy and safety of a fixed dose of asenapine in participants diagnosed with Bipolar 1 Disorder. Participants who qualify for the study will be randomly assigned to receive a fixed dose of asenapine (either 5 mg or 10 mg twice daily [BID]) or placebo (BID) for 3 weeks. Throughout the trial, observations will be made on each participant at various times to assess the safety and effectiveness of the study treatment. The primary hypothesis is that there is at least one dose of asenapine that is superior to placebo in the change from baseline in manic symptoms (as measured by Young Mania Rating Scale [YMRS]) at Day 21 of the trial.